Recent news and corporate updates regarding Lexeo Therapeutics center heavily on clinical trial progression for its pipeline of genetic medicines targeting cardiovascular diseases and Alzheimer's disease. Regulatory updates, clinical data readouts from ongoing Phase trials, and quarterly financial reports detailing cash runway metrics are published regularly through the company's official investor relations portal and major financial news distribution networks.